Literature DB >> 26143090

Sleep-disordered breathing and future cardiovascular disease risk.

Mary Ashley Cain1, Jason Ricciuti2, Judette M Louis3.   

Abstract

Sleep-disordered breathing occurs in 0.6-15% of reproductive age women. This condition is associated with an increased lifetime risk of cardiovascular disease, cardiovascular mortality, and all-cause mortality. A substantial body of evidence demonstrated increased perinatal morbidity among pregnancies affected by SDB including gestational diabetes, gestational hypertension, and preeclampsia. These same conditions are predictive of later cardiovascular disease. Treatment of SDB has been demonstrated to decrease future cardiovascular events and mortality. Screening at-risk individuals in the perinatal period can identify women with SDB, who can benefit from treatment. Continuous positive airway pressure and lifestyle interventions can decrease subsequent adverse cardiovascular health outcomes.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  obesity; preeclampsia; sleep apnea; sleep disorderd breathing

Mesh:

Year:  2015        PMID: 26143090     DOI: 10.1053/j.semperi.2015.05.010

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  3 in total

1.  Obstructive Sleep Apnea: Women's Perspective.

Authors:  Shazia Jehan; Evan Auguste; Ferdinand Zizi; Seithikurippu R Pandi-Perumal; Ravi Gupta; Hrayr Attarian; Giradin Jean-Louis; Samy I McFarlane
Journal:  J Sleep Med Disord       Date:  2016-08-25

2.  Increased risk of Eustachian tube disorders in patients with sleep-disordered breathing.

Authors:  Meng-Shih Chou; Wen-Dien Chang; Che-Chen Lin; Yu-Fen Li; Yung-An Tsou
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

3.  Mandibular Advancement Devices Prevent the Adverse Cardiac Effects of Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS).

Authors:  Chunyan Liu; Wenjing Kang; Shilong Zhang; Xing Qiao; Xiuchun Yang; Zheng Zhou; Haiyan Lu
Journal:  Sci Rep       Date:  2020-02-25       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.